AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada

AnGes MG President Ei Yamada AnGes MG President Ei Yamada said on November 28 that the company will resume the development of its investigational hepatocyte growth factor gene treatment Collategene (beperminogene perplasmid) for critical limb ischemia. “Launching Collategene is our...read more